

Recommended Adult Immunization Schedule by Age Group, United States, 2024

Vaccine	19-26 Years	27-49 Years	50-64 Years	65+ Years
Inactivated Influenza OR Recombinant Influenza (Flu)	1 dose every year ¹			
Live Attenuated Influenza (Flu)	1 dose every year ¹			
Tetanus, diphtheria, pertussis (Tdap or Td)	1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (see notes) ^{*2}			
Measles, mumps, rubella (MMR)	1 or 2 doses depending on indication (if born in 1957 or later) ^{4,5}			For healthcare personnel, see notes
Varicella (VAR)	2 doses (if born in 1980 or later) ⁶		2 doses*	
Zoster recombinant (RZV)	2 doses for immunocompromising conditions (see notes) [*]		2 doses ⁷	
Human papillomavirus (HPV)	2 or 3 doses depending on age at initial vaccination or condition ⁸	27 through 45 years		
Pneumococcal conjugate (PCV15, PCV20 or PPSV23)	1 dose ^{*9}			See Notes
Hepatitis A (HepA)	2, 3 or 4 doses depending on vaccine ^{*4}			
Hepatitis B (HepB)	2, 3 or 4 doses ⁴		2, 3 or 4 doses ^{*4}	
Meningococcal A, C, W, Y (MenACWY)	1 or 2 doses ^{*4}			
Meningococcal B (MenB)	19 through 23 years	2 or 3 doses ^{*4,10}		
<i>Haemophilus influenzae</i> type b (Hib)	1 or 3 doses ^{*4}			
Mpox				
COVID-19	1 or more doses of updated (2023–2024 Formula) vaccine (See Notes) ¹¹			
Respiratory Syncytial Virus (RSV)	Seasonal administration during pregnancy. See Notes. ^{*12}		>60 years	

Footnotes:

Follow your healthcare provider’s recommendations for special situations and during outbreaks.

- 1 dose of Flu vaccine is recommended annually, may receive live attenuated, recombinant, or inactivated flu vaccine through age 49. Only inactivated or recombinant flu vaccine should be given at age 50 and older. If you receive live attenuated vaccine, avoid contact with/caring for immunosuppressed persons for 7 days after vaccination.
- Recommended once primary series is completed unless needed for wound management, then consult ACIP recommendations.
- Pregnant women need a dose of Tdap with each pregnancy, preferably in early part of gestational weeks 27-36.
- Number of doses depends on vaccine, condition and/or indication.
- MMR should not be given during pregnancy or to someone with severe immunocompromising conditions.
- 2 doses recommended if born in 1980 or later who have previously not received 2 doses or had chickenpox, or adults with an additional risk factor or another indication.
- Doses 1 and 2 should be separated by 2-6 months. Vaccination recommended regardless of previous herpes zoster or history of zoster vaccine live (ZVL, Zostavax) vaccination.
- Doses needed depends on age at initial vaccination or condition, for ages 27-45 years vaccination is based on shared clinical decision making.
- 1 dose of PCV15 followed by PPSV23 1 year later (a minimum interval of 8 weeks can be considered for adults with immunocompromising conditions) or 1 dose of PCV20. Follow your healthcare provider’s recommendation due to age considerations and previous vaccination status.
- Vaccination recommended for ages 19-23 years without additional risk factors, or another indication is based on shared clinical decision making.
- 1 dose of updated (2023–2024 Formula) Moderna or Pfizer-BioNTech vaccine. 2-dose series of updated (2023–2024 Formula) Novavax at 0, 3–8 weeks.
- Pregnant at 32-36 weeks gestation from September through January in most of the continental United States: 1 dose RSV vaccine. Administer RSV vaccine regardless of previous RSV infection.



[Recommended Adult Immunization Schedule \(cdc.gov\)](#)



- Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection, guidance for additional information or talk to your healthcare provider.
- *Recommended vaccination for adults with an additional risk factor or another indication, see CDC guidance for additional information or talk to your healthcare provider.
- Recommended vaccination based on shared clinical decision-making